Sanaria is a biotechnology company that was established with the singular mission to develop and commercialize a malaria vaccine that is safe and effective for worldwide use. Since 2002, when it was founded, the company has been engaged in research and development on such a vaccine, and recently moved one step closer toward its mission. In August of 2013, a Phase-I clinical trial for Sanaria’s patented PfSPZ Vaccine had a 100% success rate among the trial’s volunteers who were exposed to malaria-causing parasite after receiving the highest dosage of the vaccine— no one in the group contracted malaria.
This achievement soon became the beginning of another journey for the founders of Sanaria, Dr. Stephen L. Hoffman and his wife, Dr. B. Kim Lee Sim. Their next challenge is to develop an automated mosquito dissecting robot to mass produce the vaccine. For millions of people around the world, ready availability of Sanaria's vaccine will be life-saving.
Since 2007, Sterne, Kessler, Goldstein & Fox has helped establish, secure and protect Sanaria’s intellectual property rights in the U.S. and abroad. Sterne Kessler has been successful in obtaining patent protection throughout the world for Sanaria's vaccine, the pharmaceutically useful embodiments of the vaccine immunogen, live attenuated whole parasites, as well as methods of making and using the vaccine.